Answers are grounded in this paper and cite their sources.
EML4-ALK is found in the minority of NSCLC. ALK kinase inhibitors alone or in combination may nevertheless be clinically effective treatments for NSCLC patients whose tumors contain EML4-ALK.
No takes yet. Share an insight, caveat, or question.
Koivunen et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: